Summary & Overview
HCPCS J2430: Pamidronate Disodium Injection, per 30 mg
HCPCS Level II code J2430 denotes a 30 mg unit of pamidronate disodium administered by injection. Nationally, this billing code is relevant for oncology and metabolic bone disease care, where intravenous bisphosphonate therapy is used to manage malignancy-associated bone complications and hypercalcemia. Proper unitization and site-of-service designation affect claim adjudication and aggregate spending for outpatient infusion therapy.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find benchmarks for utilization and unit pricing, guidance on typical sites of service and service-line classification, and a clinical context that links J2430 use to oncology and specialty infusion care. The publication highlights common billing considerations and payor coverage patterns without offering provider recommendations.
This summary equips billing managers, revenue cycle professionals, and policy analysts with a concise reference to how J2430 is used in outpatient infusion settings, what to expect from major payers nationally, and which clinical situations typically drive use of pamidronate disodium.
Billing Code Overview
HCPCS Level II code J2430 describes an injection of pamidronate disodium, billed per 30 mg. This code represents an intravenous medication administration of a bisphosphonate used for conditions that require bone resorption inhibition, such as malignancy-related hypercalcemia and certain metastatic bone disease scenarios.
-
Service type: Medication administration (intravenous infusion of a drug per unit dose)
-
Typical site of service: Hospital outpatient infusion center, physician office infusion suite, or other outpatient infusion setting
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with bone metastases from breast or prostate cancer, or with multiple myeloma, who requires intravenous bisphosphonate therapy for reduction of skeletal-related events and relief of bone pain. The oncology clinic receives an order for J2430 (pamidronate disodium, per 30 mg). The workflow includes verification of the diagnosis and prior authorization if needed, review of renal function and serum calcium, preparation of the dose in the outpatient infusion suite or hospital infusion center, administration via slow IV infusion over the recommended time (per institutional protocol), monitoring for infusion reactions and hypocalcemia during and for a period after infusion, documentation of lot numbers and administered units, and billing using J2430 multiplied by the number of 30 mg units infused. Typical sites of service are outpatient hospital infusion center, physician office infusion suite, or ambulatory infusion centers serving oncology and hematology patients.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Office or other outpatient visit | When reporting an evaluation and management service with the infusion in the same encounter if payer requires modifier for separate E/M |
| Increased procedural services | When clinically necessary additional work or complexity in preparing/administering infusion beyond typical service